eph rinb2  (R&D Systems)

Journal: Pharmaceuticals

Article Title: The Therapeutic Effects of EFNB2-Fc in a Cell Model of Kawasaki Disease

doi: 10.3390/ph16040500

Figure Lengend Snippet: Expression of EphB4 and EFNB2 in the cell model of KD. HCAECs were incubated in a medium containing 15% sera from HCs or KD for 6 h. ( A , B ) Protein levels of EphB4 and EFNB2 were measured by Western blot. ( C ) The mRNA expressions of EphB4 and EFNB2 were measured by RT-qPCR. All results are expressed as the mean ± SEM. * p < 0.05, ** p < 0.01 vs. the control group.

Article Snippet: Recombinant human EphrinB2 Fc chimera (EFNB2-FC, obtained from R&D) or recombinant human IgG1 Fc (IgG Fc, as a control for EFNB2-Fc, obtained from R&D) was coated at 2 μg/mL overnight at 4 °C.

Techniques: Expressing, Incubation, Western Blot, Quantitative RT-PCR

Journal: Pharmaceuticals

Article Title: The Therapeutic Effects of EFNB2-Fc in a Cell Model of Kawasaki Disease

doi: 10.3390/ph16040500

Figure Lengend Snippet: Effects of EFNB2-Fc on cell proliferation, angiogenesis ability, and inflammation. ( A ) HCAECs were seeded in plates precoated with EFNB2-Fc or IgG Fc and incubated for 24 h. The medium was then changed with 15% KD sera for six hours or not, and cell proliferation was detected by CCK-8. ( B ) HCAECs were seeded in plates precoated with EFNB2-Fc or IgG Fc, incubated for 24 h, changed medium with 15% KD sera for 6 h, and then plated on Matrigel. ( C , D ) HCAECs were seeded in plates precoated with EFNB2-Fc or IgG Fc, incubated for 24 h, and changed medium with 15% KD sera for 6 h. The protein levels of p-ERK, IL-6, and SELP were measured by Western blot. Full-length blots are presented in . All data are the mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001 vs. the control group.

Article Snippet: Recombinant human EphrinB2 Fc chimera (EFNB2-FC, obtained from R&D) or recombinant human IgG1 Fc (IgG Fc, as a control for EFNB2-Fc, obtained from R&D) was coated at 2 μg/mL overnight at 4 °C.

Techniques: Incubation, CCK-8 Assay, Western Blot

Journal: Pharmaceuticals

Article Title: The Therapeutic Effects of EFNB2-Fc in a Cell Model of Kawasaki Disease

doi: 10.3390/ph16040500

Figure Lengend Snippet: RT-qPCR primers used in this study.

Article Snippet: Recombinant human EphrinB2 Fc chimera (EFNB2-FC, obtained from R&D) or recombinant human IgG1 Fc (IgG Fc, as a control for EFNB2-Fc, obtained from R&D) was coated at 2 μg/mL overnight at 4 °C.

Techniques: